FDA Human Factors Guidance 2026 Update for Device Submissions

The FDA human factors guidance 2026 update (finalized May 29, 2026) revises the requirements for submitting human factors (HF) information in medical device marketing submissions. The updated guidance from the U.S. Food and Drug Administration (FDA) introduces new risk-based submission categories, expands examples for modified devices, and clarifies expectations for sponsors preparing 510(k), De Novo, and PMA applications. The changes apply to medical devices, including combination products, and significantly impact how manufacturers classify and justify human factors validation activities.

Overview of the FDA Human Factors Guidance 2026 Update

The updated guidance titled “Content of Human Factors Information in Medical Device Marketing Submissions” issued by the FDA provides a revised framework for determining what human factors information must be included in regulatory submissions.

It applies to:

• 510(k) submissions

• De Novo requests

• Premarket Approval (PMA) applications

• Combination products

The guidance reinforces the importance of usability engineering and risk-based validation in demonstrating safe and effective device use.

Key Changes in the 2026 FDA Human Factors Guidance

The 2026 update introduces several important modifications:

1. New risk-based HF submission categories

The FDA now defines clearer Human Factors Submission Categories (1, 2, and 3) based on risk and device modification complexity.

2. Expanded guidance for modified devices

Sponsors must now assess whether design changes affect user interaction risks and whether full or partial HF validation is required.

3. Expanded Appendix examples

The updated guidance includes detailed case examples:

• Reusable duodenoscope

• Stereotaxic navigation system

• Continuous glucose monitor (CGM)

• Interoperable automated glycemic controller for type 1 diabetes management

These examples illustrate how HF expectations vary based on intended use and risk profile.

Human Factors Submission Categories Explained

The FDA introduces structured categorization for human factors submissions:

HF Submission Category 1

Typically applies to:

• Low-risk modifications

• Minimal changes to user interface

• Limited new use-related risks

HF Submission Category 2

Applies to:

• Moderate design changes

• Changes affecting critical user tasks

• Devices with partial usability impact

HF Submission Category 3

Applies to:

• High-risk devices or major redesigns

• New user interfaces or workflows

• Complex systems with significant use-related hazards

Manufacturers must now justify category selection based on use-related risk analysis and design impact assessment.

Impact on Medical Device Marketing Submissions

The updated guidance affects all major regulatory pathways under FDA oversight.

Key implications:

• Increased emphasis on early usability risk assessment

• More structured justification for HF study design

• Stronger alignment between design controls and HF validation

• Greater scrutiny of modified and interoperable devices

Sponsors must now integrate human factors planning earlier in the product development lifecycle to avoid submission delays.

How to Determine the Correct HF Submission Category

Manufacturers should evaluate:

• Intended use and user population

• Severity of potential use errors

• Device complexity and interface changes

• Interoperability and system integration risks

• Whether prior HF validation remains applicable

A structured risk-based approach is now essential to ensure correct classification under the new framework.

Internal References

• FDA US Medical Device Registration

External Reference (FDA Guidance Document)

• FDA Human Factors Guidance (May 2026 update)